MiNK Therapeutics (NASDAQ:INKT – Get Free Report) issued its quarterly earnings data on Friday. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.20, Zacks reports.
Here are the key takeaways from MiNK Therapeutics’ conference call:
- MiNK said its AGENT-797 iNKT platform continues to show encouraging signals across oncology and critical illness, including durable survival in refractory gastric cancer and immune modulation in ARDS and lung injury.
- The company initiated a randomized phase II ARDS trial of AGENT-797 versus placebo on top of standard of care, with a planned seamless phase II/III design and FDA discussions expected in the coming weeks.
- Management highlighted translational data showing the same donor-derived product can generate different immune responses depending on disease state, supporting a potential biomarker-driven approach for patient selection in ARDS.
- MiNK’s cash position of about $9.5 million at quarter-end, plus operational efficiencies and non-dilutive collaboration support, is expected to fund at least the next 12 months of operations, including the randomized trial launch.
- The company also expanded its pipeline and partnership strategy through a C-Further collaboration for a PRAME-targeted TCR-engineered iNKT program in pediatric cancers and said it will present additional data, including an ANKTIVA combination study, at upcoming medical meetings.
MiNK Therapeutics Stock Performance
Shares of MiNK Therapeutics stock opened at $10.72 on Friday. The firm has a 50-day moving average of $11.00 and a 200-day moving average of $11.61. MiNK Therapeutics has a 52-week low of $6.65 and a 52-week high of $76.00. The stock has a market cap of $53.41 million, a PE ratio of -3.61 and a beta of 0.47.
Institutional Trading of MiNK Therapeutics
Wall Street Analyst Weigh In
A number of research analysts recently commented on the stock. Weiss Ratings lowered shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of MiNK Therapeutics in a research report on Wednesday, April 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $35.00.
View Our Latest Research Report on INKT
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.
MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.
Read More
- Five stocks we like better than MiNK Therapeutics
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
